Community-Informed Interventions for Equitable Congestive Heart Failure Management in Primary Care
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Amber Woltzen
- Phone Number: 507-422-6732
- Email: woltzen.amber@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Amber Woltzen
- Phone Number: 507-422-6732
- Email: woltzen.amber@mayo.edu
-
Principal Investigator:
- Majken T. Wingo, MD
-
Principal Investigator:
- Jane W. Njeru, MB, ChB
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients living with congestive heart failure (CHF):
- Age 18 years or older.
- Diagnosis or clinical documentation of CHF or heart failure in the Mayo Clinic medical record.
- Empaneled in Mayo Clinic, Rochester, primary care
- Evidence in the EHR of one or more adverse SDoH, elevated utilization, medical/social complexity.
- Able to provide informed consent.
- Able to participate in study procedures.
Caregivers:
- Age 18 years or older.
- Caregiver with relevant lived, caregiving, or community experience related to CHF, and nominated by the patient.
- Able to provide informed consent
- Able to participate in study procedures.
Community health worker and care-team stakeholders:
- Age 18 years or older.
- Current or recent role relevant to CHF care, transitions of care, SDoH, patient education, or CHW workflows.
- Able to provide informed consent
- Able to participate in study procedures.
Exclusion Criteria:
- Under age 18 years.
- Unable or unwilling to provide informed consent.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Adults living with congestive heart failure (CHF)
Adults living with CHF receiving primary care at Mayo Clinic Rochester with adverse SDoH, elevated utilization, or related medical/social complexity
|
Participants will be asked to complete an individual interview or participate in a group discussion lasting approximately 60 to 120 minutes, conducted in person, by telephone, or by Mayo-approved video platform.
Interview and discussion guides will include discussion of barriers, facilitators, preferences, priorities, and care gaps related to congestive heart failure self-care, access, transitions of care, community health worker support, caregiver support, social needs, health literacy, language access, trust, and culturally responsive care.
|
|
Caregivers or family members of eligible congestive heart failure (CHF) patients
Caregivers or family members of eligible CHF patients nominated by the patient
|
Participants will be asked to complete an individual interview or participate in a group discussion lasting approximately 60 to 120 minutes, conducted in person, by telephone, or by Mayo-approved video platform.
Interview and discussion guides will include discussion of barriers, facilitators, preferences, priorities, and care gaps related to congestive heart failure self-care, access, transitions of care, community health worker support, caregiver support, social needs, health literacy, language access, trust, and culturally responsive care.
|
|
Community health workers and care-team stakeholders
Community health workers, chronic disease RN care coordinators, education specialists, clinicians, and operational leaders
|
Participants will be asked to complete an individual interview or participate in a group discussion lasting approximately 60 to 120 minutes.
Interview and discussion guides will focus on development of a community health worker competency-based training module and development of workflows for community health workers to support congestive heart failure patients' self-management and care transitions.
Participants will provide feedback on implementation barriers and facilitators, including training burden, role clarity, sustainability, cultural responsiveness, and integration with clinical care teams.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identification of prioritized barriers to self-care
Time Frame: Through study completion, an average of 2 years
|
Total number of prioritized barriers to equitable congestive heart failure self-care and transitions-of-care support identified through participant interviews and group discussions.
|
Through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Majken T. Wingo, MD, Mayo Clinic
- Principal Investigator: Jane W. Njeru, MB, ChB, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Heart Diseases
- Heart Failure
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Health Care Facilities Workforce and Services
- Health Personnel
- Allied Health Personnel
- Interviews as Topic
- Caregivers
- Community Health Workers
Other Study ID Numbers
Other Study ID Numbers
- 25-013641
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.